Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression

Akira Yokoi1, Junro Kuromitsu, Takatoshi Kawai

  • 1Laboratory of Seeds Finding Technology, Eisai Co. Ltd., Ibaraki 300-2635, Japan.

Molecular Cancer Therapeutics
|December 7, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Preclinical Evaluation of Liposomal Eribulin (E7389-LF) in a Panel of Sarcoma Patient-Derived Xenograft Models.

Molecular cancer therapeutics·2026
Same author

Recurrence after Long-Term Use of Poly ADP-Ribose Polymerase Inhibitors Triggered by Therapy-Related Myeloid Neoplasms: A Case Report.

Case reports in oncology·2026
Same author

Transcriptome profiling identifies RET activation as a therapeutic target in gastric-type endocervical adenocarcinoma.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Extracellular vesicles in nipple discharge for breast cancer screening.

Breast cancer research and treatment·2026
Same author

Rapid Enlargement of Vulvar Glomus Tumor After Needle Aspiration and Tumor Base Ligation.

The journal of obstetrics and gynaecology research·2026
Same author

Impact of Sarcopenia and Pretreatment Skeletal Muscle Loss on Survival in Endometrial Cancer Patients Treated With Immune Checkpoint Inhibitors.

The journal of obstetrics and gynaecology research·2026

Novel sulfonamide compounds were evaluated as antitumor agents, revealing two distinct classes of cell cycle inhibitors. One class disrupts tubulin polymerization, while the other affects gene expression in metabolic and immune pathways.

Area of Science:

  • Medicinal Chemistry
  • Molecular Pharmacology
  • Oncology

Background:

  • Sulfonamide derivatives are explored for novel antitumor properties.
  • Previous research identified potential cell cycle inhibitors within sulfonamide libraries.

Purpose of the Study:

  • To characterize two distinct classes of sulfonamide-based cell cycle inhibitors.
  • To investigate the gene expression profiles associated with these antitumor sulfonamides.
  • To identify potential pharmacodynamic markers for clinical assessment.

Main Methods:

  • Cell-based screening using flow cytometry to identify cell cycle inhibitors.
  • Oligonucleotide microarray analysis to assess gene expression changes.
  • Phenotypic screening and gene expression profiling of sulfonamide compounds.

Related Experiment Videos

Main Results:

  • Two classes of inhibitors were identified: microtubule-disrupting agents (E7010, ER-67865) and compounds with unknown mechanisms affecting S-phase and G1/G2 phases (E7070, ER-68487).
  • Microtubule inhibitors down-regulated alpha-tubulin transcripts, consistent with their mechanism.
  • The second class of compounds repressed genes involved in metabolism, cell cycle, immune response, and signal transduction.
  • Compounds E7010 and E7070 showed objective responses in Phase I clinical trials.

Conclusions:

  • Sulfonamide compounds exhibit distinct mechanisms of action as antitumor agents.
  • Gene expression profiling provides insights into the molecular effects of these compounds.
  • This research supports the development of sulfonamides as anticancer therapeutics and suggests potential clinical biomarkers.